Cardiovascular disease: risk assessment and reduction, including lipid modification
KEYWORDS: people, cvd, risk, treatment, statin, statins, committee, recommendations, prevention, evidence, cholesterol, recommendation, lipid-lowering, primary, amended

what determines future health (this may affect their attitude to changing risk) • assess their readiness to make changes to their lifestyle (diet, physical activity, smoking and alcohol consumption), to undergo investigations and to take long-term medication • assess their confidence to make changes to their lifestyle, undergo investigations and take medication • inform them of potential future management options based on current evidence and best practice • involve them in developing a shared management plan • check that they have understood what has been discussed. [2008, amended 2014] 1.1.18 If the person's CVD risk is at a level where treatment is recommended but they decline the offer of treatment, advise them that their CVD risk should be reassessed in the future. Record their choice in their medical records. [2008, amended 2014] For a short explanation of why the committee made the 2023 recommendation and how it might affect practice, see the rationale and impact section on communication about risk assessment, lifestyle changes and treatment. Full details of the evidence and the committee's discussion are in evidence review A: CVD risk assessment tools: primary prevention. 1.2 Aspirin for primary prevention of cardiovascular disease 1.2.1 Do not routinely offer aspirin for
